5 results about "Enterovirus Infections" patented technology

The present disclosure relates to animal models that express human tryptophanyl-tRNA synthetase (hWARS) knock-in. These animal models are highly susceptible to enterovirus infection, including but not limited to EV-D68 and EV-A71 infection. Also disclosed are screening methods and compounds that utilize these animal models.

The application discloses an oil and fat composition for resisting porcine enterovirus infection and application thereof. The oil and fat composition comprises at least two of glyceryl monopentanoate, glyceryl monolinoleate and glyceryl monomyristate. The oil and fat composition can further comprise anhydrous ethanol, propylene glycol, dimethyl sulfoxide, edible oil, Tween 80, lactose, mannitol, soluble starch, water and other auxiliary materials for preparing oil and fat composition preparations. The oil and fat composition can inhibit enterovirus through multiple channels and multiple levels, and improve the antiviral effect. Adding the oil and fat composition in the feed of pigs can not only improve the antiviral ability, but also reduce the inflammatory reaction caused by pathogenic infection through the anti-inflammatory and immune regulation effects, effectively prevent and treat the infection of porcine enterovirus diarrhea, and thus reduce the incidence of porcine enterovirus diarrhea and the mortality of pigs with the disease. The oil and fat composition can be used for preparing a medicine or a feed additive for treating and preventing porcine enterovirus diarrhea.

The application discloses a kind of compounds or its pharmaceutically acceptable salt, crystal form, solvate shown in formula I;Wherein, R1, R2, R3, R4 It is independently selected from halogen, C1~C4 Alkyl or halogen-substituted C1~C4 Alkyl.This kind of compound, it is connected by amido group with para-substituted phenyl and 3,5 position substituted benzyl to thiophene, novel and unique structure, to EV71, EVD68 Such as multiple enterovirus has good inhibitory activity and smaller cytotoxicity, provides a new potential choice for enterovirus infection with pharmacy drug.In addition, the application also discloses the preparation method and application of the compound shown in formula I, and its pharmaceutical composition.

[Solution] This disclosure describes a method for treating a respiratory enterovirus infection in a human subject having COPD, comprising the steps of: administering to the subject a therapeutically effective dose of bapendavir or a pharmaceutically acceptable salt thereof; and thereby treating the respiratory enterovirus infection in the subject. Pharmaceutical formulations of bapendavir are also disclosed.

In an aspect, the invention relates to compositions and methods for treating sepsis, including but not limited neonatal sepsis and sepsis related to infection. In an aspect, the invention relates to compositions and methods for attenuating adverse conditions of sepsis resulting from enterovirus infection. In an aspect, the invention relates to improved formulations of antiviral agents such as pleconaril for the treatment, alleviation and prevention of conditions associated with sepsis.